⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5792673 | 0.93 | FAAH (0.43) | — | |
| SCHEMBL366668 | 0.84 | — | — | |
| SCHEMBL21815374 | 0.84 | NOS3 (0.38) | — | |
| SCHEMBL28903229 | 0.84 | NOS3 (0.38) | — | |
| SCHEMBL30957285 | 0.81 | EPHX2 (0.40) | — | |
| SCHEMBL15103300 | 0.81 | EPHX2 (0.40) | — | |
| SCHEMBL8376071 | 0.81 | EPHX2 (0.40) | — | |
| SCHEMBL27260555 | 0.78 | — | — | |
| SCHEMBL3763074 | 0.78 | NPC1 (0.36) | — | |
| SCHEMBL1934062 | 0.77 | ALDH1A1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113372273-A | Ivabradine intermediate compound IV | 鲁南制药集团股份有限公司 | 2021-09-10 | — | — | CN | claimed |
| EP-4347607-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4341272-A1 | METHOD FOR PREPARING A LIBRARY OF PEPTIDES OR A PEPTIDE | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2024-03-27 | — | — | EP | disclosed |
| EP-3458459-B1 | MACROCYCLIC INDOLE DERIVATIVES | BAYER AG (DE) | 2022-04-27 | — | — | EP | disclosed |
| US-10981932-B2 | Macrocyclic indole derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-20 | — | — | US | disclosed |
| US-20200087322-A1 | MACROCYCLIC INDOLE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-03-19 | — | — | US | disclosed |
| EP-3458459-A1 | MACROCYCLIC INDOLE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2019-03-27 | — | — | EP | disclosed |
| WO-2017198341-A1 | MACROCYCLIC INDOLE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2017-11-23 | — | — | WO | disclosed |
| EP-2718283-A1 | INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2014-04-16 | — | — | EP | disclosed |
| US-8415468-B2 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2013-04-09 | — | — | US | disclosed |
| WO-2012169649-A1 | INDAZOLE- AND PYRROLOPYRIDINE-DERIVATIVE AND PHARMACEUTICAL USE THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-12-13 | — | — | WO | disclosed |
| US-20110294999-A1 | PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | LES LABORATOIRES SERVIER (FR) | 2011-12-01 | — | — | US | disclosed |
| WO-2011007091-A1 | DERIVATIVES OF 5,6-BISARYL-2-PYRIDINE-CARBOXAMIDE, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS UROTENSIN-II RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2011-01-20 | — | — | WO | disclosed |
| US-20100160628-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2010-06-24 | — | — | US | disclosed |
| CN-100445281-C | Quinuclidine derivatives binding to muscarinic M3 receptor | NOVARTIS AG (CH) | 2008-12-24 | — | — | CN | disclosed |
| CN-1784400-A | Quinuclidine derivatives binding to muscarinic M3 receptor | NOVARTIS AG (CH) | 2006-06-07 | — | — | CN | disclosed |